Characterisation of a secreted MFSD6-Fc microbody as a decoy receptor for respiratory enterovirus D68

Zhaoxue Li1, Huili Li1, Xize Liu1

  • 1Cancer Centre, The First Hospital of Jilin University, Changchun, Jilin, 130021, China; Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, Jilin, 130021, China.

Ebiomedicine
|September 9, 2025
PubMed
Abstract

Insights

A novel decoy receptor targeting MFSD6 effectively neutralizes Enterovirus D68 (EV-D68), significantly reducing viral attachment and increasing survival rates in mice. This approach shows promise for developing new EV-D68 therapies.

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Enterovirus D68 (EV-D68) causes severe respiratory illness and polio-like symptoms in children.
  • MFSD6 was recently identified as a key receptor for EV-D68 entry into host cells.
  • Targeting the EV-D68-MFSD6 interaction presents a potential therapeutic strategy.

Purpose of the Study:

  • To engineer an MFSD6-based decoy receptor to neutralize EV-D68.
  • To investigate the mechanism of action of this decoy receptor.
  • To evaluate the therapeutic efficacy of the decoy receptor against EV-D68 infection.

Main Methods:

  • Engineered a secreted MFSD6-Fc microbody (secMFSD6 Mb).
  • Assessed binding and neutralization using in vitro assays (co-immunoprecipitation, RT-qPCR) and electron microscopy.
  • Evaluated efficacy in EV-D68-infected cell lines and a neonatal mouse model.

Main Results:

  • secMFSD6 Mb reduced EV-D68 attachment to cells by over 90%.
  • Electron microscopy revealed conversion of intact virions to empty capsids upon treatment.
  • In vivo, secMFSD6 Mb increased 15-day survival in mice from 11% to 89%.

Conclusions:

  • The MFSD6-based decoy receptor effectively neutralizes EV-D68.
  • This strategy demonstrates potential for developing novel therapeutics against EV-D68.
  • Further development of decoy receptor strategies could combat EV-D68 infections.